Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 13/20 | 0.77 |
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL981931 | 0.89 | PDPK1 (0.81) | PDPK1MAPTSMN1; SMN2TP53THRB | |
| SCHEMBL4277893 | 0.89 | PDPK1 (0.70) | PDPK1MAPTSMN1; SMN2TP53THRB | |
| Ar-12 SCHEMBL570472 | 0.87 | PDPK1 (1.00) | PDPK1MAPTSMN1; SMN2TP53THRB | |
| Ar-12 SCHEMBL30099806 | 0.87 | PDPK1 (1.00) | PDPK1MAPTSMN1; SMN2TP53THRB | |
| SCHEMBL17077243 | 0.85 | PDPK1 (0.75) | PDPK1MAPTSMN1; SMN2TP53THRB | |
| SCHEMBL978868 | 0.84 | PDPK1 (1.00) | PDPK1MAPTSMN1; SMN2TP53 | |
| SCHEMBL982210 | 0.82 | PDPK1 (0.78) | PDPK1MAPT | |
| SCHEMBL980502 | 0.82 | PDPK1 (0.78) | PDPK1MAPT | |
| SCHEMBL16195901 | 0.82 | PDPK1 (0.91) | PDPK1MAPTSMN1; SMN2TP53THRB | |
| SCHEMBL978943 | 0.82 | PDPK1 (0.85) | PDPK1MAPTSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741944-B2 | Anti-infective agents against intracellular pathogens | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-06-03 | — | — | US | disclosed |
| US-8541460-B2 | Phosphoinositide-dependent kinase-1 (PDK-1) inhibitors; for the treatment and prevention of cancer in humans; 4-[5-(2-Phenanthracenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenecarboxamide | THE OHIO STATE UNIVERSITY (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130237575-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-09-12 | — | — | US | disclosed |
| US-8445483-B1 | Anti-infective agents against intracellular pathogens | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-21 | — | — | US | disclosed |
| US-20130109681-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-02 | — | — | US | disclosed |
| US-8080574-B2 | PDK-1/Akt signaling inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-12-20 | — | — | US | disclosed |
| US-8039502-B2 | Anti-infective agents against intracellular pathogens | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110015242-A1 | PDK-1/AKT SIGNALING INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2011-01-20 | — | — | US | disclosed |
| US-7576116-B2 | PDK-1/Akt signaling inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-08-18 | — | — | US | disclosed |
| US-20090111799-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-04-30 | — | — | US | disclosed |
| US-20080269309-A1 | PDK-1/AKT SIGNALING INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080146815-A1 | PDK-1/AKT SIGNALING INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2008-06-19 | — | — | US | disclosed |
| US-20060079566-A1 | PDK-1/Akt signaling inhibitors | THE NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015242-A1 | PDK-1/AKT SIGNALING INHIBITORS | PDPK1, TNNI3K, MAP3K1 | PDPK1 1/4885MAPT 4759/4885SMN1; SMN2 3791/4885 |
| US-20060079566-A1 | PDK-1/Akt signaling inhibitors | PDPK1, PDXK, PDK3 | PDPK1 1/4885MAPT 4725/4885SMN1; SMN2 4653/4885 |
| US-20130237575-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | PDPK1, PLK3, SIK3 | PDPK1 1/4885MAPT 4155/4885SMN1; SMN2 4353/4885 |
| US-20080146815-A1 | PDK-1/AKT SIGNALING INHIBITORS | PDPK1, PDXK, PI4KA | PDPK1 1/4885MAPT 4754/4885SMN1; SMN2 4611/4885 |
| US-20080269309-A1 | PDK-1/AKT SIGNALING INHIBITORS | PDPK1, TNNI3K, MAP3K1 | PDPK1 1/4885MAPT 4759/4885SMN1; SMN2 3791/4885 |
| US-20130109681-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | PDPK1, PLK3, SIK3 | PDPK1 1/4885MAPT 4155/4885SMN1; SMN2 4353/4885 |
| US-20090111799-A1 | ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS | PDPK1, PLK3, SIK3 | PDPK1 1/4885MAPT 4155/4885SMN1; SMN2 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.